Name : Human DLL4 Protein
Product Source :
Recombinant Human DLL4 Protein is expressed from HEK293 with His tag at the C-terminus. It contains Ser27-Pro524.[Accession | KT340-D]
Molecular Weight :
The protein has a predicted MW of 55.38 kDa. Due to glycosylation, the protein migrates to 56-70 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 90% as determined by HPLC
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, 200 mM L-Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human DLL4 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human DLL4 is greater than 90% as determined by SEC-HPLC. ELISA Data Immobilized Human DLL4, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-DLL4 Antibody, hFc Tag with the EC50 of 11.8ng/ml determined by ELISA.
Background :
Delta-like protein 4 (DLL4) is a type I membrane protein belonging to the Delta/Serrate/Lag2 (DSL) family of Notch ligands. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate.
Synonyms :
DLL4; MGC126344; notch ligand DLL4; Delta4; Delta-like 4
References & Citations :
(1)Gurney A , Hoey T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action[J]. Vascular Cell, 2011, 3(1):18.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
S100A13 Proteinsupplier
EGF ProteinAccession
Popular categories:
C1-Inhibitor
Toll-like Receptor 9